Myovant Sciences Price to Book Ratio 2017-2022 | MYOV

Historical price to book ratio values for Myovant Sciences (MYOV) over the last 10 years. The current price to book ratio for Myovant Sciences as of January 25, 2023 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Myovant Sciences Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2023-01-26 26.90 0.00
2022-09-30 17.96 $-5.32 -3.38
2022-06-30 12.43 $-5.05 -2.46
2022-03-31 13.32 $-4.99 -2.67
2021-12-31 15.57 $-4.62 -3.37
2021-09-30 22.44 $-4.11 -5.45
2021-06-30 22.77 $-4.35 -5.24
2021-03-31 20.58 $-3.89 -5.29
2020-12-31 27.62 $-2.98 -9.27
2020-09-30 14.05 $-2.21 -6.37
2020-06-30 20.62 $-1.49 -13.81
2020-03-31 7.55 $-1.21 -6.26
2019-12-31 15.52 $-0.54 -28.50
2019-09-30 5.20 $0.19 27.01
2019-06-30 9.05 $0.89 10.19
2019-03-31 23.87 $0.06 397.17
2018-12-31 16.41 $0.66 24.86
2018-09-30 26.55 $1.23 21.67
2018-06-30 22.87 $0.93 24.67
2018-03-31 21.27 $0.62 34.39
2017-12-31 12.64 $1.35 9.38
2017-09-30 15.47 $1.95 7.93
2017-06-30 11.70 $2.40 4.88
2017-03-31 11.74 $2.77 4.24
2016-12-31 12.44 $3.09 4.03
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.604B $0.231B
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.571B 9.49
GSK (GSK) United Kingdom $71.996B 8.97
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.433B 19.52
Ginkgo Bioworks Holdings (DNA) United States $3.414B 0.00
Arcus Biosciences (RCUS) United States $1.676B 25.16
Biohaven (BHVN) United States $1.305B 0.00
Emergent Biosolutions (EBS) United States $0.671B 5.28
ADC Therapeutics SA (ADCT) Switzerland $0.359B 0.00
Ambrx Biopharma (AMAM) United States $0.083B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.028B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00